Details About Generic Salt ::  Dacarbaz

Main Medicine Class::    

(da-CAR-buh-zeen)

DTIC-Dome

Powder for injection

10 mg/mL

Class: Alkylating agent

Triazene

 Indications Metastatic malignant melanoma, combination therapy of Hodgkin disease.

Soft-tissue sarcomas.

 Contraindications Standard considerations.

 Route/Dosage

Malignant Melanoma

ADULTS: IV Dacarbazine 250 mg/m²/day for 5 days; may repeat at 3-wk intervals.

Hodgkin Lymphoma (Combination Therapy)

ADULTS: IV Dacarbazine 150 mg/m²/day for 5 days; may be repeated at 4-wk intervals. Alternative regimen is 375 mg/m² IV on day 1; repeated q 15 days.

Adjustment in Renal or Hepatic Insufficiency

ADULTS: IV Dosage adjustment in hepatic or renal insufficiency is warranted; however, there are no specific guidelines.

Interactions None well documented.

Lab Test Interferences None well documented.

 Adverse Reactions

CNS: Facial paresthesias; confusion; headache; seizures. DERMATOLOGIC: Alopecia; facial flushing; erythematous or urticarial rash. GI: Nausea; vomiting; anorexia; hepatic veno-occlusive disease. HEMATOLOGIC: Bone marrow suppression. OTHER: Flu-like syndrome; fever; myalgias; malaise.

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Extravasation: Local irritation or phlebitis may occur. Refer to the institution’s specific protocol. GI: Anorexia, nausea, and vomiting occur in over 90% of patients with the initial few doses. Hemopoietic depression: Hemopoietic depression is the most common toxicity and involves primarily the leukocytes and platelets, although anemia sometimes occurs. Leukopenia and thrombocytopenia may be severe enough to cause death. Possible bone marrow depression requires careful monitoring of WBC, RBC, and platelet levels. Hepatotoxicity: Hepatotoxicity, accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death, reported. Hypersensitivity: Anaphylaxis can occur.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Refrigerate unreconstituted powder; protect from light. Powder can be stored at room temperature (59° to 86°F) for up to 4 wk.
• Reconstitute powder with Sterile Water for Injection. For an isotonic solution for IV injections, 5% Dextrose or 0.9% Sodium Chloride can be used.
• Reconstitute 100 mg/vial with 9.9 mL diluent for a final concentration of 10 mg/mL. Reconstitute 200 mg/vial with 19.7 mL diluent for a final concentration of 10 mg/mL.
• Reconstituted 10 mg/mL solution may be further diluted with up to 250 mL of 5% Dextrose or 0.9% Sodium Chloride for IV infusion.
• Although stable in the refrigerator for up to 72 hr, reconstituted dacarbazine contains no preservative; use within 24 hr. At room temperature, it is stable for up to 8 hr.
• Solutions diluted further with 5% Dextrose or 0.9% Sodium Chloride are stable under refrigeration for up to 24 hr or at room temperature for 8 hr. For continuous infusion regimens, dacarbazine may be mixed in the same bag with doxorubicin.
• Dacarbazine solutions must be protected from sunlight; protection from normal room lighting is unnecessary.
• Color change of solution from ivory to pink indicates decomposition.
• Administer by IV injection, IV infusion, or continuous IV infusion.
• Administer reconstituted 10 mg/mL solution by IV push over 1 to 2 min in freely running IV solution.
• Diluted solutions may be infused IV over 15 to 30 min or by continuous infusion over 24 hr.

 Assessment/Interventions

• Monitor CBC and LFTs at baseline, and throughout therapy.

 Patient/Family Education

• Explain name, dose, action, and potential side effects of drug.
• Advise patient, family, or caregiver that medication will be prepared and administered by health care provider in a health care setting.
• Review dosing schedule with patient, family, or caregiver.
• Advise patient, family, or caregiver that restricting food intake for 4 to 6 hr before treatment may reduce frequency and severity of nausea and vomiting.
• Advise patient, family, or caregiver that hot packs may be applied to injection site to relieve pain, irritation, or burning sensation.
• Advise patient, family, or caregiver to immediately report any of the following to health care provider: rash; hives; difficulty breathing; fever, chills, or other signs of infection; sore throat; unusual bleeding or bruising.
• Advise patient, family, or caregiver to report any of the following to health care provider: persistent nausea, vomiting or appetite loss; persistent fatigue, general body discomfort or muscle aches; injection site reaction that does not improve with hot pack applications.
• Advise patient, family, or caregiver that drug may cause photosensitivity and to avoid unnecessary exposure to the sun and other UV light (eg, tanning booths). Advise patient to use sunscreens and wear protective clothing until tolerance is determined.
• Instruct patient to not take any prescription or otc medications or dietary supplements unless advised by health care provider.
• Instruct women of childbearing potential to notify health care provider if becoming pregnant, planning on becoming pregnant, or are breastfeeding.
• Advise patient that frequent follow-up visits and laboratory tests will be required to monitor therapy and to keep appointments.

Medicscientist Drug Facts

Drugs Class ::

Indications for Drugs ::

 Indications Metastatic malignant melanoma, combination therapy of Hodgkin disease.

Soft-tissue sarcomas.

Drug Dose ::

 Route/Dosage

Malignant Melanoma

ADULTS: IV Dacarbazine 250 mg/m²/day for 5 days; may repeat at 3-wk intervals.

Hodgkin Lymphoma (Combination Therapy)

ADULTS: IV Dacarbazine 150 mg/m²/day for 5 days; may be repeated at 4-wk intervals. Alternative regimen is 375 mg/m² IV on day 1; repeated q 15 days.

Adjustment in Renal or Hepatic Insufficiency

ADULTS: IV Dosage adjustment in hepatic or renal insufficiency is warranted; however, there are no specific guidelines.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Extravasation: Local irritation or phlebitis may occur. Refer to the institution’s specific protocol. GI: Anorexia, nausea, and vomiting occur in over 90% of patients with the initial few doses. Hemopoietic depression: Hemopoietic depression is the most common toxicity and involves primarily the leukocytes and platelets, although anemia sometimes occurs. Leukopenia and thrombocytopenia may be severe enough to cause death. Possible bone marrow depression requires careful monitoring of WBC, RBC, and platelet levels. Hepatotoxicity: Hepatotoxicity, accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death, reported. Hypersensitivity: Anaphylaxis can occur.

Drug Side Effects ::

 Adverse Reactions

CNS: Facial paresthesias; confusion; headache; seizures. DERMATOLOGIC: Alopecia; facial flushing; erythematous or urticarial rash. GI: Nausea; vomiting; anorexia; hepatic veno-occlusive disease. HEMATOLOGIC: Bone marrow suppression. OTHER: Flu-like syndrome; fever; myalgias; malaise.

Drug Mode of Action ::  

Drug Interactions ::

Interactions None well documented.

Drug Assesment ::

 Assessment/Interventions

• Monitor CBC and LFTs at baseline, and throughout therapy.

Drug Storage/Management ::

 Administration/Storage

• Refrigerate unreconstituted powder; protect from light. Powder can be stored at room temperature (59° to 86°F) for up to 4 wk.
• Reconstitute powder with Sterile Water for Injection. For an isotonic solution for IV injections, 5% Dextrose or 0.9% Sodium Chloride can be used.
• Reconstitute 100 mg/vial with 9.9 mL diluent for a final concentration of 10 mg/mL. Reconstitute 200 mg/vial with 19.7 mL diluent for a final concentration of 10 mg/mL.
• Reconstituted 10 mg/mL solution may be further diluted with up to 250 mL of 5% Dextrose or 0.9% Sodium Chloride for IV infusion.
• Although stable in the refrigerator for up to 72 hr, reconstituted dacarbazine contains no preservative; use within 24 hr. At room temperature, it is stable for up to 8 hr.
• Solutions diluted further with 5% Dextrose or 0.9% Sodium Chloride are stable under refrigeration for up to 24 hr or at room temperature for 8 hr. For continuous infusion regimens, dacarbazine may be mixed in the same bag with doxorubicin.
• Dacarbazine solutions must be protected from sunlight; protection from normal room lighting is unnecessary.
• Color change of solution from ivory to pink indicates decomposition.
• Administer by IV injection, IV infusion, or continuous IV infusion.
• Administer reconstituted 10 mg/mL solution by IV push over 1 to 2 min in freely running IV solution.
• Diluted solutions may be infused IV over 15 to 30 min or by continuous infusion over 24 hr.

Drug Notes ::

 Patient/Family Education

• Explain name, dose, action, and potential side effects of drug.
• Advise patient, family, or caregiver that medication will be prepared and administered by health care provider in a health care setting.
• Review dosing schedule with patient, family, or caregiver.
• Advise patient, family, or caregiver that restricting food intake for 4 to 6 hr before treatment may reduce frequency and severity of nausea and vomiting.
• Advise patient, family, or caregiver that hot packs may be applied to injection site to relieve pain, irritation, or burning sensation.
• Advise patient, family, or caregiver to immediately report any of the following to health care provider: rash; hives; difficulty breathing; fever, chills, or other signs of infection; sore throat; unusual bleeding or bruising.
• Advise patient, family, or caregiver to report any of the following to health care provider: persistent nausea, vomiting or appetite loss; persistent fatigue, general body discomfort or muscle aches; injection site reaction that does not improve with hot pack applications.
• Advise patient, family, or caregiver that drug may cause photosensitivity and to avoid unnecessary exposure to the sun and other UV light (eg, tanning booths). Advise patient to use sunscreens and wear protective clothing until tolerance is determined.
• Instruct patient to not take any prescription or otc medications or dietary supplements unless advised by health care provider.
• Instruct women of childbearing potential to notify health care provider if becoming pregnant, planning on becoming pregnant, or are breastfeeding.
• Advise patient that frequent follow-up visits and laboratory tests will be required to monitor therapy and to keep appointments.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.